Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma

Blood (2022) 139 (3): 384–398.

https://doi.org/10.1182/blood.2020010039

Published: 2022

Includes: Supplemental data

Journal Articles

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Blood (2021) 137 (24): 3390–3402.

https://doi.org/10.1182/blood.2020008729

Published: 2021

Includes: Supplemental data

Journal Articles

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

Jitka Fucikova, Iva Truxova, Michal Hensler, Etienne Becht, Lenka Kasikova, Irena Moserova, Sarka Vosahlikova, Jana Klouckova, Sarah E. Church, Isabelle Cremer, Oliver Kepp, Guido Kroemer, Lorenzo Galluzzi, Cyril Salek, Radek Spisek

Blood (2016) 128 (26): 3113–3124.

https://doi.org/10.1182/blood-2016-08-731737

Published: 2016

Includes: Supplemental data

Journal Articles

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Elodie Lainey, Marie Sebert, Cyrielle Bouteloup, Carole Leroy, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, MD, Guido Kroemer, MD, PhD, Pierre Fenaux, MD, PhD, Simone Boehrer, MD, PhD

Blood (2011) 118 (21): 2564.

https://doi.org/10.1182/blood.V118.21.2564.2564

Published: 2011

Journal Articles

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Marie Sebert, Elodie Lainey, PAscale Lepelley, Sylvain Thepot, Maximilien Tailler, Claude Gardin, MD, Guido Kroemer, MD, PhD, Simone Boehrer, Lionel Ades, Pierre Fenaux, MD, PhD

Blood (2011) 118 (21): 5028.

https://doi.org/10.1182/blood.V118.21.5028.5028

Published: 2011

Journal Articles

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Blood (2011) 118 (21): 2790.

https://doi.org/10.1182/blood.V118.21.2790.2790

Published: 2011

Journal Articles

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Marie Sebert, Elodie Lainey, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, Pierre Fenaux, MD, PhD, Guido Kroemer, Simone Boehrer

Blood (2010) 116 (21): 2163.

https://doi.org/10.1182/blood.V116.21.2163.2163

Published: 2010

Journal Articles

Hypomethylating Agents Correct Subcellular Localization of FOXO3a and (re)Establish Expression of Its Transcriptional Targets In AML and MDS- Cells

Sylvain Thepot, Elodie Lainey, Marie Sebert, Lionel Ades, Claude Gardin, Pierre Fenaux, MD, PhD, Guido Kroemer, Simone Boehrer

Blood (2010) 116 (21): 2173.

https://doi.org/10.1182/blood.V116.21.2173.2173

Published: 2010

Journal Articles

Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters

Elodie Lainey, Marie Sebert, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, Guido Kroemer, Pierre Fenaux, MD, PhD, Simone Boehrer

Blood (2010) 116 (21): 974.

https://doi.org/10.1182/blood.V116.21.974.974

Published: 2010

Journal Articles

The multifaceted granulysin

Laurence Zitvogel, Guido Kroemer

Blood (2010) 116 (18): 3379–3380.

https://doi.org/10.1182/blood-2010-08-299214

Published: 2010

Journal Articles

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

Simone Boehrer, MD, PhD, Lorenzo Galluzzi, phD, Lionel Ades, MD, Celine Fouassier, Claude Gardin, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2009) 114 (22): 3813.

https://doi.org/10.1182/blood.V114.22.3813.3813

Published: 2009

Journal Articles

The dilemma of anticancer therapy: tumor-specific versus immune effects

Laurence Zitvogel, Guido Kroemer

Blood (2008) 112 (12): 4364–4365.

https://doi.org/10.1182/blood-2008-09-176693

Published: 2008

Journal Articles

The Capacity of the Hypomethylating Agents Azacytidine and Decitabine to Induce Apoptosis and Cell Cycle Arrest Depends on the Activation of the DNA-Damage Response Pathway.

Simone Boehrer, Lionel Ades, Nicolas Tajeddine, Lorenzo Galluzzi, Stephane de Botton, Pierre Fenaux, Guido Kroemer

Blood (2008) 112 (11): 1655.

https://doi.org/10.1182/blood.V112.11.1655.1655

Published: 2008

Journal Articles

Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome.

Simone Boehrer, Lionel Ades, Nicolas Tajeddine, Lorenzo Galluzzi, Wolf-Karsten Hofmann, Pierre Fenaux, Guido Kroemer

Blood (2008) 112 (11): 1656.

https://doi.org/10.1182/blood.V112.11.1656.1656

Published: 2008

Journal Articles

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Simone Boehrer, Lionel Adès, Thorsten Braun, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, Génèviève Le Roux, Claude Gardin, Antoine Martin, Stéphane de Botton, Pierre Fenaux, Guido Kroemer

Blood (2008) 111 (4): 2170–2180.

https://doi.org/10.1182/blood-2007-07-100362

Published: 2008

Includes: Supplemental data

Journal Articles

Flt3 Receptor Inhibition Abolishes Constitutive NFκB Activation in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Jennifer Grosjean, PhD, Lionel Ades, MD, Simone Bohrer, MD, PhD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 2434.

https://doi.org/10.1182/blood.V110.11.2434.2434

Published: 2007

Journal Articles

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Simone Boehrer, MD, Lionel Ades, MD, Lorenzo Galluzzi, Ken Olaussen, PhD, Thorsten Braun, MD, Jennifer Grosjean, PhD, Claire Fabre, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 2438.

https://doi.org/10.1182/blood.V110.11.2438.2438

Published: 2007

Journal Articles

Disruption of Bcl-2 Heterodimerization by the BH3 Mimetic ABT-737 Restores Spontaneous Apoptosis and Induces Differentiation in High Risk MDS and AML.

L. Ades, MD, S. Boehrer, MD, T. Braun, MD, J. Grosjean, MD, C. Fabre, MD, Pierre Fenaux, MD, Guido Kroemer, MD

Blood (2007) 110 (11): 398.

https://doi.org/10.1182/blood.V110.11.398.398

Published: 2007

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, MD, Lionel Ades, MD, Thorsten Braun, MD, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, MD, Genevieve Le Roux, Claude Gardin, MD, Antoine Martin, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 399.

https://doi.org/10.1182/blood.V110.11.399.399

Published: 2007

Journal Articles

Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach

Hana Raslova, Audrey Kauffmann, Dalila Sekkaï, Hugues Ripoche, Fréderic Larbret, Thomas Robert, Diana Tronik Le Roux, Guido Kroemer, Najet Debili, Philippe Dessen, Vladimir Lazar, William Vainchenker

Blood (2006) 109 (8): 3225–3234.

https://doi.org/10.1182/blood-2006-07-037838

Published: 2006

Includes: Supplemental data

NARROW

The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Hypomethylating Agents Correct Subcellular Localization of FOXO3a and (re)Establish Expression of Its Transcriptional Targets In AML and MDS- Cells

Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters

The multifaceted granulysin

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

The dilemma of anticancer therapy: tumor-specific versus immune effects

The Capacity of the Hypomethylating Agents Azacytidine and Decitabine to Induce Apoptosis and Cell Cycle Arrest Depends on the Activation of the DNA-Damage Response Pathway.

Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome.

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Flt3 Receptor Inhibition Abolishes Constitutive NFκB Activation in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Disruption of Bcl-2 Heterodimerization by the BH3 Mimetic ABT-737 Restores Spontaneous Apoptosis and Induces Differentiation in High Risk MDS and AML.

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only